{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T01:10:09Z","timestamp":1749777009162,"version":"3.41.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,12]]},"DOI":"10.7759\/cureus.85873","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:47:30Z","timestamp":1749775650000},"source":"Crossref","is-referenced-by-count":0,"title":["Recurrent Pleural Effusion in an Elderly Patient With Chronic Myeloid Leukemia Following Tyrosine Kinase Inhibitor Therapy"],"prefix":"10.7759","author":[{"given":"Mohammad","family":"Abed Alhaleem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafa","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luxhman","family":"Gunaseelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Easow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian H","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, et al.. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010, 362:2260-70. 10.1056\/NEJMoa1002315","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0449-7","article-title":"Tyrosine kinase inhibitors in the treatment of chronic-phase CML: strategies for frontline decision-making","volume":"13","author":"Kennedy JA","year":"2018","unstructured":"Kennedy JA, Hobbs G. Tyrosine kinase inhibitors in the treatment of chronic-phase CML: strategies for frontline decision-making. Curr Hematol Malig Rep. 2018, 13:202-11. 10.1007\/s11899-018-0449-7","journal-title":"Curr Hematol Malig Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quint\u00e1s-Cardama A","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R, Cortes J. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007, 25:3908-14. 10.1200\/JCO.2007.12.0329","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200705-715CR","article-title":"Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series","volume":"176","author":"Bergeron A","year":"2007","unstructured":"Bergeron A, R\u00e9a D, Levy V, et al.. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007, 176:814-8. 10.1164\/rccm.200705-715CR","journal-title":"Am J Respir Crit Care Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka K","year":"2008","unstructured":"Porkka K, Koskenvesa P, Lund\u00e1n T, et al.. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008, 112:1005-12. 10.1182\/blood-2008-02-140665","journal-title":"Blood"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?","volume":"105","author":"Atallah E","year":"2020","unstructured":"Atallah E, Schiffer CA. Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?. Haematologica. 2020, 105:2738-45. 10.3324\/haematol.2019.242891","journal-title":"Haematologica"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2306","article-title":"Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study","volume":"165","author":"Dahl\u00e9n T","year":"2016","unstructured":"Dahl\u00e9n T, Edgren G, Lambe M, et al.. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med. 2016, 165:161-6. 10.7326\/M15-2306","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour E","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024, 99:2191-212. 10.1002\/ajh.27443","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib versus Imatinib Study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, et al.. Final 5-year study results of DASISION: the Dasatinib versus Imatinib Study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016, 34:2333-40. 10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes TP","year":"2016","unstructured":"Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016, 128:17-23. 10.1182\/blood-2016-01-694265","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/371528-recurrent-pleural-effusion-in-an-elderly-patient-with-chronic-myeloid-leukemia-following-tyrosine-kinase-inhibitor-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:47:31Z","timestamp":1749775651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/371528-recurrent-pleural-effusion-in-an-elderly-patient-with-chronic-myeloid-leukemia-following-tyrosine-kinase-inhibitor-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.85873","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,12]]}}}